BBOTBridgeBio Oncology Therapeutics, Inc.

Sign up free

Market reactionShares fell 12% on Nov 2.

IntactLast material event Sep 8, 2026 · Updated Oct 26, 2026

BBO-8520 with pembrolizumab must hold its early response rate in mid-2027 data

BridgeBio Oncology Therapeutics develops oral pills that block the KRAS cancer gene; its lead, BBO-8520, is being tested with pembrolizumab in lung cancer, and nothing is approved.

BBO-8520 blocks both the active and inactive forms of KRAS G12C. With pembrolizumab, in lung cancer that progressed on an earlier G12C drug, the response rate was 53% across doses in 17 patients and 75% at 500 mg. Alone, it produced a 63% response rate in patients not previously given a G12C drug. BBOT now focuses on the combination, with expanded data due in mid-2027. BBO-11818 and BBO-10203 updates come in the fourth quarter. Cash of $344.1 million lasts into 2028.

Thesis checklist

0 risks need attention

Select a row for evidence
BBO-8520 combination response holds at scaleAwaiting evidenceNext: Expanded dataset in mid-2027.

Why it is in this state

The evidence, what would weaken it and the source filing

Monotherapy activity in untreated G12C patientsSupportedNext: Durability updates.

Why it is in this state

The evidence, what would weaken it and the source filing

BBO-11818 and BBO-10203 show activityAwaiting evidenceNext: Fourth-quarter 2026 monotherapy update.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash lasts into 2028SupportedNext: Quarterly cash updates.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

Expanded BBO-8520 plus pembrolizumab data

Tests: BBO-8520 combination response holds at scale

Mid-2027 (company)

Does BBO-8520 with pembrolizumab keep a high, durable response rate in more G12C-inhibitor-experienced patients?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentClinical
-23.8%Sep 8, 2026

BBO-8520 with pembrolizumab must hold its early response rate in mid-2027 data

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

KRAS G12C mutant NSCLC· previously treated
BBO-8520 · 1 upcoming · 3 completed
Phase 1 DataONKORAS-101
Mid 2027
KRAS-mutant cancers
BBO-11818, BBO-10203 · 1 upcoming
Data
Q4 2026
Colorectal cancer and pancreatic ductal adenocarcinoma· KRAS-mutant
BBO-11818, BBO-10203 · 1 upcoming
Data
Mid 2027
KRAS mutant solid tumors
BBO-11818 · 1 completed
Phase 1 Data: InterimKONQUER-101
Reported Mar 5, 2026
HER2+ breast cancer, KRAS-mutant solid tumors
BBO-10203 · 1 completed
Phase 1 Data: InterimBREAKER-101
Reported Jan 7, 2026

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the BridgeBio Oncology Therapeutics (BBOT) investment thesis intact?
Yes. Readouts currently rates the BridgeBio Oncology Therapeutics Thesis Intact. BBO-8520 with pembrolizumab must hold its early response rate in mid-2027 data.
What is the next catalyst for BridgeBio Oncology Therapeutics (BBOT)?
The next dated event is Results for BBO-11818, BBO-10203, expected Q4 2026, as stated by the company. Also ahead: Phase 1 results (ONKORAS-101) for BBO-8520, expected mid-2027.
How long will BridgeBio Oncology Therapeutics' cash last?
BridgeBio Oncology Therapeutics has said its cash will fund operations into 2028 (guidance as of September 8, 2026).

Other companies we cover in these diseases

Pancreatic ductal adenocarcinoma
Erasca (ERAS)

Disease areas: Lung cancer, Breast and gynecologic cancers, Gastrointestinal cancers, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

6 peers tracked

For informational purposes only—not investment advice. Always conduct your own research before making investment decisions.

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.